glp-1 drug updates Medicare is about to cover drugs for weight loss. Here's what to know The promises and pitfalls of
Description
Retatrutide (Triple GLP-1R/GIPR/GCGR agonist (LY3437943)) is a 39-amino acid triple-receptor peptide
A significant concern is that the most common adverse effects of GLP-1 agonistsnausea, vomiting, diarrhea, and abdominal painoverlap substantially with Crohn's disease symptoms

In response, GLP-1 is released and signals to the body that enough food has been consumed

Users are warned about thyroid cancer, pancreatitis, kidney problems, gallbladder disease, and allergic reactions

How will these drugs be integrated into our healthcare system, and what factors will facilitate widespread adoption

Frontiers In Cardiovascular Medicine 9:966968 Gibb AA, Murray EK, Eaton DM, Huynh AT, Tomar D, Garbincius JF, Kolmetzky DW, Berretta RM, Wallner M, Houser SR, Elrod JW (2021) Molecular signature of HFpEF: systems biology in a cardiac-centric large animal model
